Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly

Wannisa Khamaikawin, Somphot Saoin, Sawitree Nangola, Koollawat Chupradit, Supachai Sakkhachornphop, Sudarat Hadpech, Nattawat Onlamoon, Aftab A. Ansari, Siddappa N. Byrareddy, Pierre Boulanger, Saw See Hong, Bruce E. Torbett, Chatchai Tayapiwatana

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Designed molecular scaffolds have been proposed as alternative therapeutic agents against HIV-1. The ankyrin repeat protein (AnkGAG 1D4) and the zinc finger protein (2LTRZFP) have recently been characterized as intracellular antivirals, but these molecules, used individually, do not completely block HIV-1 replication and propagation. The capsid-binder AnkGAG1D4, which inhibits HIV-1 assembly, does not prevent the genome integration of newly incoming viruses. 2LTRZFP, designed to target the 2-LTR-circle junction of HIV-1 cDNA and block HIV-1 integration, would have no antiviral effect on HIV-1-infected cells. However, simultaneous expression of these two molecules should combine the advantage of preventive and curative treatments. To test this hypothesis, the genes encoding the N-myristoylated Myr(+)AnkGAG1D4 protein and the 2LTRZFP were introduced into human T-cells, using a third-generation lentiviral vector. SupT1 cells stably expressing 2LTRZFP alone or with Myr(+)AnkGAG1D4 showed a complete resistance to HIV-1 in viral challenge. Administration of the Myr(+)AnkGAG1D4 vector to HIV-1-preinfected SupT1 cells resulted in a significant antiviral effect. Resistance to viral infection was also observed in primary human CD4+ T-cells stably expressing Myr(+)AnkGAG1D4, and challenged with HIV-1, SIVmac, or SHIV. Our data suggest that our two anti-HIV-1 molecular scaffold prototypes are promising antiviral agents for anti-HIV-1 gene therapy.

Original languageEnglish (US)
Article numbere249
Pages (from-to)e249
JournalMolecular Therapy - Nucleic Acids
Volume4
DOIs
StatePublished - Aug 25 2015

Fingerprint

Capsid
Antiviral Agents
HIV-1
Genome
Therapeutics
Ankyrin Repeat
T-Lymphocytes
Proteins
Zinc Fingers
Virus Diseases
Genetic Therapy
Complementary DNA
Viruses

Keywords

  • Anti-HIV-1 molecular scaffolds
  • HIV-1-resistant cells
  • SHIV
  • SIV
  • designed ankyrin repeat proteins
  • designed zinc-finger proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly. / Khamaikawin, Wannisa; Saoin, Somphot; Nangola, Sawitree; Chupradit, Koollawat; Sakkhachornphop, Supachai; Hadpech, Sudarat; Onlamoon, Nattawat; Ansari, Aftab A.; Byrareddy, Siddappa N.; Boulanger, Pierre; Hong, Saw See; Torbett, Bruce E.; Tayapiwatana, Chatchai.

In: Molecular Therapy - Nucleic Acids, Vol. 4, e249, 25.08.2015, p. e249.

Research output: Contribution to journalArticle

Khamaikawin, W, Saoin, S, Nangola, S, Chupradit, K, Sakkhachornphop, S, Hadpech, S, Onlamoon, N, Ansari, AA, Byrareddy, SN, Boulanger, P, Hong, SS, Torbett, BE & Tayapiwatana, C 2015, 'Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly', Molecular Therapy - Nucleic Acids, vol. 4, e249, pp. e249. https://doi.org/10.1038/mtna.2015.22
Khamaikawin, Wannisa ; Saoin, Somphot ; Nangola, Sawitree ; Chupradit, Koollawat ; Sakkhachornphop, Supachai ; Hadpech, Sudarat ; Onlamoon, Nattawat ; Ansari, Aftab A. ; Byrareddy, Siddappa N. ; Boulanger, Pierre ; Hong, Saw See ; Torbett, Bruce E. ; Tayapiwatana, Chatchai. / Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly. In: Molecular Therapy - Nucleic Acids. 2015 ; Vol. 4. pp. e249.
@article{142f4eda69364937bbf28ad2a19e6ea7,
title = "Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly",
abstract = "Designed molecular scaffolds have been proposed as alternative therapeutic agents against HIV-1. The ankyrin repeat protein (AnkGAG 1D4) and the zinc finger protein (2LTRZFP) have recently been characterized as intracellular antivirals, but these molecules, used individually, do not completely block HIV-1 replication and propagation. The capsid-binder AnkGAG1D4, which inhibits HIV-1 assembly, does not prevent the genome integration of newly incoming viruses. 2LTRZFP, designed to target the 2-LTR-circle junction of HIV-1 cDNA and block HIV-1 integration, would have no antiviral effect on HIV-1-infected cells. However, simultaneous expression of these two molecules should combine the advantage of preventive and curative treatments. To test this hypothesis, the genes encoding the N-myristoylated Myr(+)AnkGAG1D4 protein and the 2LTRZFP were introduced into human T-cells, using a third-generation lentiviral vector. SupT1 cells stably expressing 2LTRZFP alone or with Myr(+)AnkGAG1D4 showed a complete resistance to HIV-1 in viral challenge. Administration of the Myr(+)AnkGAG1D4 vector to HIV-1-preinfected SupT1 cells resulted in a significant antiviral effect. Resistance to viral infection was also observed in primary human CD4+ T-cells stably expressing Myr(+)AnkGAG1D4, and challenged with HIV-1, SIVmac, or SHIV. Our data suggest that our two anti-HIV-1 molecular scaffold prototypes are promising antiviral agents for anti-HIV-1 gene therapy.",
keywords = "Anti-HIV-1 molecular scaffolds, HIV-1-resistant cells, SHIV, SIV, designed ankyrin repeat proteins, designed zinc-finger proteins",
author = "Wannisa Khamaikawin and Somphot Saoin and Sawitree Nangola and Koollawat Chupradit and Supachai Sakkhachornphop and Sudarat Hadpech and Nattawat Onlamoon and Ansari, {Aftab A.} and Byrareddy, {Siddappa N.} and Pierre Boulanger and Hong, {Saw See} and Torbett, {Bruce E.} and Chatchai Tayapiwatana",
year = "2015",
month = "8",
day = "25",
doi = "10.1038/mtna.2015.22",
language = "English (US)",
volume = "4",
pages = "e249",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly

AU - Khamaikawin, Wannisa

AU - Saoin, Somphot

AU - Nangola, Sawitree

AU - Chupradit, Koollawat

AU - Sakkhachornphop, Supachai

AU - Hadpech, Sudarat

AU - Onlamoon, Nattawat

AU - Ansari, Aftab A.

AU - Byrareddy, Siddappa N.

AU - Boulanger, Pierre

AU - Hong, Saw See

AU - Torbett, Bruce E.

AU - Tayapiwatana, Chatchai

PY - 2015/8/25

Y1 - 2015/8/25

N2 - Designed molecular scaffolds have been proposed as alternative therapeutic agents against HIV-1. The ankyrin repeat protein (AnkGAG 1D4) and the zinc finger protein (2LTRZFP) have recently been characterized as intracellular antivirals, but these molecules, used individually, do not completely block HIV-1 replication and propagation. The capsid-binder AnkGAG1D4, which inhibits HIV-1 assembly, does not prevent the genome integration of newly incoming viruses. 2LTRZFP, designed to target the 2-LTR-circle junction of HIV-1 cDNA and block HIV-1 integration, would have no antiviral effect on HIV-1-infected cells. However, simultaneous expression of these two molecules should combine the advantage of preventive and curative treatments. To test this hypothesis, the genes encoding the N-myristoylated Myr(+)AnkGAG1D4 protein and the 2LTRZFP were introduced into human T-cells, using a third-generation lentiviral vector. SupT1 cells stably expressing 2LTRZFP alone or with Myr(+)AnkGAG1D4 showed a complete resistance to HIV-1 in viral challenge. Administration of the Myr(+)AnkGAG1D4 vector to HIV-1-preinfected SupT1 cells resulted in a significant antiviral effect. Resistance to viral infection was also observed in primary human CD4+ T-cells stably expressing Myr(+)AnkGAG1D4, and challenged with HIV-1, SIVmac, or SHIV. Our data suggest that our two anti-HIV-1 molecular scaffold prototypes are promising antiviral agents for anti-HIV-1 gene therapy.

AB - Designed molecular scaffolds have been proposed as alternative therapeutic agents against HIV-1. The ankyrin repeat protein (AnkGAG 1D4) and the zinc finger protein (2LTRZFP) have recently been characterized as intracellular antivirals, but these molecules, used individually, do not completely block HIV-1 replication and propagation. The capsid-binder AnkGAG1D4, which inhibits HIV-1 assembly, does not prevent the genome integration of newly incoming viruses. 2LTRZFP, designed to target the 2-LTR-circle junction of HIV-1 cDNA and block HIV-1 integration, would have no antiviral effect on HIV-1-infected cells. However, simultaneous expression of these two molecules should combine the advantage of preventive and curative treatments. To test this hypothesis, the genes encoding the N-myristoylated Myr(+)AnkGAG1D4 protein and the 2LTRZFP were introduced into human T-cells, using a third-generation lentiviral vector. SupT1 cells stably expressing 2LTRZFP alone or with Myr(+)AnkGAG1D4 showed a complete resistance to HIV-1 in viral challenge. Administration of the Myr(+)AnkGAG1D4 vector to HIV-1-preinfected SupT1 cells resulted in a significant antiviral effect. Resistance to viral infection was also observed in primary human CD4+ T-cells stably expressing Myr(+)AnkGAG1D4, and challenged with HIV-1, SIVmac, or SHIV. Our data suggest that our two anti-HIV-1 molecular scaffold prototypes are promising antiviral agents for anti-HIV-1 gene therapy.

KW - Anti-HIV-1 molecular scaffolds

KW - HIV-1-resistant cells

KW - SHIV

KW - SIV

KW - designed ankyrin repeat proteins

KW - designed zinc-finger proteins

UR - http://www.scopus.com/inward/record.url?scp=84940053734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940053734&partnerID=8YFLogxK

U2 - 10.1038/mtna.2015.22

DO - 10.1038/mtna.2015.22

M3 - Article

C2 - 26305555

AN - SCOPUS:84940053734

VL - 4

SP - e249

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

M1 - e249

ER -